The Rundown: ExL’s Blog
Viewing 61 to 70 of 96 records.
Pfizer Executive Previews the 8th Clinical Quality Oversight Forum in New Interview
Sunday June 18th, 2017
One of our esteemed faculty speakers recently sat down with AppliedClinicalTrialsOnline.com to discuss clinical trial quality events, which of course led to some greatly appreciated ExL conference previews! The subject of this interview is Dr. Jonathan Rowe, Executive Director and Head of Clinical Development Quality Performance and Risk Management, at Pfizer. Jonathan is speaking at our 8th Clinical Quality Oversight Forum and touches on his upcoming session in the interview.
Rowe, who recently spoke at ExL’s CROWN Congress, also answers questions regarding Pfizer’s tactics for managing clinical trial…
13th Pharmaceutical Meeting Professionals Summit to Be Held November 6–7, 2017 at the Hilton Philadelphia at Penn’s Landing
Thursday June 15th, 2017
The 13th Pharmaceutical Meeting Professionals Summit will be held on November 6–7, 2017 at the Hilton Philadelphia at Penn’s Landing. This interactive summit attracts 200+ senior-level meeting professionals working in the pharmaceutical, biotechnology, and medical device industries, and acts as their annual gathering to learn, engage, and network.
With well over 60% of the 2016 audience representing meeting planners and with 57% of them having more than 10 years of experience in the events industry, this is the ideal forum to learn from and meet with industry veterans to understand current trends, innovation and efficient strategies for optimizing medical meeting…
GSK Acquires PRV for ViiV’s Two-Drug HIV Therapy, Beating Gilead to Billion-Dollar Market
Thursday June 8th, 2017
Late last week, ViiV Healthcare filed applications with both the European Medicines Agency (EMA) and U.S. Food and Drug Administration (FDA) for the world’s first two-drug HIV maintenance therapy. The treatment will also be the first of its kind on the market thanks to a surprising priority review voucher (PRV) acquisition by ViiV’s majority owner, GlaxoSmithKline – capitalizing on the multi-billion-dollar HIV market four months earlier than competitors Gilead’s HIV treatment.
Instead of the usual 10-month application process, this PRV allows ViiV, and therefore GSK, to have it completed in six months. For more information on PRVs, check out…
The Benefits of Clinical Trials for Cancer Patients, According to a Survivor
Friday June 2nd, 2017
Twelve years after T.J. Sharpe’s successful melanoma surgery, the husband and father-of-two saw the return of his skin cancer. Faced once again with the unexpected realization of mortality after more than a decade of remission, a clinical trial helped ensure Sharpe would see his children grow up. This patient and survivor is helping spread the word about clinical trials, and how they should be an available option for others like him.
The return of Sharpe’s melanoma was accompanied by a predicted life expectancy of less than two years. He was adamant on…
Top 10 U.S. Pharma Patent Losses of 2017
Monday May 29th, 2017
As we come approach the midway mark of 2017, we can’t help but wonder how the passage of time is affecting the pharmaceutical industry. Regarding U.S. patents on certain drugs, some big-name pharma companies are looking at big-time losses in 2017. Companies like Takeda, Pfizer, Gilead, Eli Lilly, and Bristol-Myers Squibb are doing their best to hold onto these coveted drug patents, but odds are that they won’t have such great luck. According to a recently published content report from FiercePharma, a handful of popular drug patents in the U.S. are expiring.
To give you an idea…
Top 10 Pharma R&D Budgets
Monday May 22nd, 2017
Since drug pricing was a noted talking point of the 2016 presidential election, it might not come as a surprise that R&D budgets in the pharmaceutical industry have seen big cuts as a result. And while this comes across as a negative, reduced spending on pharma R&D – though resulting in staff cuts, restructured operations, and more – actually resulted in positive percentage terms in sales. Luckily for us, FierceBiotech has made this information easy to understand in a recently published content report.
R&D spending varied from company to company, but overall,…
ExL Partners with the Medical Affairs Professional Society (MAPS)!
Thursday May 18th, 2017
ExL Events is excited to announce that we’ve been selected as the exclusive conference partner on a series of promotional, event service, and content exchange with the Medical Affairs Professional Society (MAPS)! While MAPS is a relatively new association, it has proved itself as one of the most formidable organizations in the medical affairs segment. MAPS has been impressing the ExL team since we started covering it in the early 2000s. Find out more about our new partner below!
ExL Events’ co-founder and COO, Ethan Denkensohn, had this to say about the exciting…
Senate Confirms New Head of FDA: Two-Time ExL Speaker Dr. Scott Gottlieb
Monday May 15th, 2017
ExL Events would like to congratulate our speaker alumnus Dr. Scott Gottlieb for the recent United States Senate confirmation, naming him the new Food and Drug Administration commissioner. Dr. Gottlieb was the keynote speaker at ExL’s 2nd Trial Design Innovation Conference and was also a featured speaker at our Private Fee-for-Service event.
President Donald Trump nominated Gottlieb earlier this year, for his previous service as deputy commissioner for the FDA, as well as his experience in the pharmaceutical and health care industries. As the FDA’s newly appointed commissioner, Gottlieb will…
Key Stakeholders Gather This Fall to Discuss Abuse-Deterrent Formulations, Regulations and Policies
Tuesday October 18th, 2016
|Dan Cohen, Forum Chair, Abuse Deterrent Coalition|
This guest blog post is written by Dan Cohen, the Forum Chair of the Abuse Deterrent Coalition and speaker at the 3rd Human Abuse Liability & Abuse-Deterrent Formulations conference, which takes place in Arlington, VA this November 2-3.
The prominence of Abuse Deterrent Formulations (ADF) in the public policy debate has never been greater. This fall is no exception as we are now at yet another critical juncture for the ADF sector, with…
Questex Acquires ExL Events
Monday July 11th, 2016
Acquisition of Leading Life Sciences Event Company Expands Company’s Services in Pharmaceutical, Life Science and Healthcare Markets
Questex, a leading global business information and events company, today announced it has acquired ExL Events, Inc., expanding Questex’s presence in the global pharmaceutical, life science and healthcare markets.
ExL Events, founded in 2004 as ExL Pharma, is the industry leader in developing innovative, educational conferences that serve the pharmaceutical, life science and healthcare communities. Kerry Gumas, Questex President and Chief Executive Officer,…
From The Blog
- Commercial Strategy
- Content Marketing
- Data Management
- Digital Marketing
- Drug Safety
- Emerging Markets
- ExL Events News
- Medical Devices
- Medical Education
- Meeting Planning
- Patient Engagement
- Public/Government Relations
- Regulatory Affairs